clinical trial · NCT04644068
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca·phase2·active not recruiting·n = 702
Ovarian CancerBreast CancerPancreatic CancerProstate CancerAdditional Indications Below for Module 4 and 5Non-small Cell Lung CancerColorectal CancerBladder CancerAZD5305PaclitaxelCarboplatinT- DxdDato-DXdCamizestrant
brief summary
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
started
Nov 12, 2020
primary completion
May 28, 2027
completion
May 28, 2027
last updated
Feb 19, 2026
detailed description
This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.
official title
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol